Tango Therapeutics (United States)
company in Cambridge, United States
TNGX Nasdaq
SEC CIK 1819133
Follow Tango Therapeutics (United States)
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$68.4M
−530.6% vs same quarter last year
EPS, diluted
−$0.39
−400% vs same quarter last year
Operating cash flow
−$37.1M
−20% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $62.4M | −$101.6M |
| FY24 | $42.1M | −$130.3M |
| FY23 | $36.5M | −$101.7M |
| FY22 | $24.9M | −$108.2M |
| FY21 | $37M | −$58.2M |
| FY20 | $7.7M | −$52M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −178.4% | −162.9% |
| FY24 | −346.1% | −309.7% |
| FY23 | −312.6% | −278.4% |
| FY22 | −446.8% | −435.1% |
| FY21 | −157.1% | −157.2% |
| FY20 | −681.8% | −678.8% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$139.9M |
| FY24 | −$132.3M |
| FY23 | −$119.5M |
| FY22 | −$116.8M |
| FY21 | −$61.4M |
| FY20 | $69M |
| FY19 | - |
- Tango Therapeutics (United States)
- Healthcare median
Show the numbers
| Year | Tango Therapeutics (United States) | Healthcare median |
|---|---|---|
| FY25 | −162.9% | −30.6% |
| FY24 | −309.7% | −47% |
| FY23 | −278.4% | −58% |
| FY22 | −435.1% | −80.4% |
| FY21 | −157.2% | −71.9% |
| FY20 | −678.8% | −62.2% |
| FY19 | - | −46.3% |